Peptides are rapidly gaining traction as a key area within longevity medicine, with a substantial black market valued between $1 billion and $3 billion. Some larger companies in this illicit market are reportedly generating as much as $2 million per month in gross sales. Even smaller businesses, like Compound Sciences, can achieve revenues of about $100,000 monthly, with half of that being profit, solely through personal referrals.
Despite the growing interest, particularly online for conditions such as sagging skin and arthritis, concerns about regulation and health risks persist. Telehealth prescriptions for peptides have raised red flags, with experts like Professor Samaras warning of potential side effects such as fluid retention, osteoarthritis, inflammation, deranged glucose metabolism, and an increased risk of diabetes. The recommendation for follow-up blood tests only a month after starting treatment is also seen as a concern, as it typically takes three months to reach peak levels from growth hormone-stimulating peptides, suggesting a lack of proper medical understanding or oversight.
The market for peptides is dynamic, with importers using evasive tactics to avoid customs detection. The reported value of imported raw materials is often just a fraction of the consumer price, which can range from $50 to $300 per vial, compared to a few dollars for large importers. This thriving parallel market highlights both the demand for peptide therapies and the challenges regulators face in controlling their distribution and use, as the push to make these therapies more widely available continues.
